Comparison of short‐term outcomes following minimally invasive versus open Sweet esophagectomy for Siewert type <scp>II</scp> adenocarcinoma of the esophagogastric junction

Sun, Xiaohui; Wang, Gaoxiang; Liu, Changqing; Xiong, Ran; Wu, Hanran; Xu, Shibin

doi:10.1111/1759-7714.13415

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carcinoma of the esophagogastric junction (CEGJ) is defined as a carcinoma whose center is located within 5 cm above and below the esophagogastric anatomical junction and crosses the esophagogastric junction (EGJ). Due to the short and narrow EGJ site and the up-and-down invasive nature of the CEGJ, its biological behavior is different from that of gastric or esophageal cancer[ 1 - 3 ]. The Siewert staging, which is widely accepted in academia, classifies CEGJ into types I, II, and III based on the distance between the tumor center and the EGJ[ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Application of computed tomography-based radiomics in differential diagnosis of adenocarcinoma and squamous cell carcinoma at the esophagogastric junction

Du¹,

Huang²,

Liu³

et al. 2022

WJG

View full text Add to dashboard Cite

BACKGROUND The biological behavior of carcinoma of the esophagogastric junction (CEGJ) is different from that of gastric or esophageal cancer. Differentiating squamous cell carcinoma of the esophagogastric junction (SCCEG) from adenocarcinoma of the esophagogastric junction (AEG) can indicate Siewert stage and whether the surgical route for patients with CEGJ is transthoracic or transabdominal, as well as aid in determining the extent of lymph node dissection. With the development of neoadjuvant therapy, preoperative determination of pathological type can help in the selection of neoadjuvant radiotherapy and chemotherapy regimens. AIM To establish and evaluate computed tomography (CT)-based multiscale and multiphase radiomics models to distinguish SCCEG and AEG preoperatively. METHODS We retrospectively analyzed the preoperative contrasted-enhanced CT imaging data of single-center patients with pathologically confirmed SCCEG ( n = 130) and AEG ( n = 130). The data were divided into either a training ( n = 182) or a test group ( n = 78) at a ratio of 7:3. A total of 1409 radiomics features were separately extracted from two dimensional (2D) or three dimensional (3D) regions of interest in arterial and venous phases. Intra-/inter-observer consistency analysis, correlation analysis, univariate analysis, least absolute shrinkage and selection operator regression, and backward stepwise logical regression were applied for feature selection. Totally, six logistic regression models were established based on 2D and 3D multi-phase features. The receiver operating characteristic curve analysis, the continuous net reclassification improvement (NRI), and the integrated discrimination improvement (IDI) were used for assessing model discrimination performance. Calibration and decision curves were used to assess the calibration and clinical usefulness of the model, respectively. RESULTS The 2D-venous model (5 features, AUC: 0.849) performed better than 2D-arterial (5 features, AUC: 0.808). The 2D-arterial-venous combined model could further enhance the performance (AUC: 0.869). The 3D-venous model (7 features, AUC: 0.877) performed better than 3D-arterial (10 features, AUC: 0.876). And the 3D-arterial-venous combined model (AUC: 0.904) outperformed other single-phase-based models. The venous model showed a positive improvement compared with the arterial model (NRI > 0, IDI > 0), and the 3D-venous and combined models showed a significant positive improvement compared with the 2D-venous and combined models ( P < 0.05). Decision curve analysis showed that combined 3D-arterial-venous model and 3D-venous model had a higher net clinical benefit within the same threshold probability range in the test group. CONCLUSION The combined arterial-venous CT radiomics model based o...

show abstract

Section: Introductionmentioning

confidence: 99%

Application of computed tomography-based radiomics in differential diagnosis of adenocarcinoma and squamous cell carcinoma at the esophagogastric junction

Du¹,

Huang²,

Liu³

et al. 2022

WJG

View full text Add to dashboard Cite

show abstract

Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Kitagawa,

Matsuda,

Gotoda

et al. 2024

Gastric Cancer

View full text Add to dashboard Cite

Pharmacological effects and mechanisms of paeonol on antitumor and prevention of side effects of cancer therapy

Chang

Feng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer represents one of the leading causes of mortality worldwide. Conventional clinical treatments include radiation therapy, chemotherapy, immunotherapy, and targeted therapy. However, these treatments have inherent limitations, such as multidrug resistance and the induction of short- and long-term multiple organ damage, ultimately leading to a significant decrease in cancer survivors’ quality of life and life expectancy. Paeonol, a nature active compound derived from the root bark of the medicinal plant Paeonia suffruticosa, exhibits various pharmacological activities. Extensive research has demonstrated that paeonol exhibits substantial anticancer effects in various cancer, both in vitro and in vivo. Its underlying mechanisms involve the induction of apoptosis, the inhibition of cell proliferation, invasion and migration, angiogenesis, cell cycle arrest, autophagy, regulating tumor immunity and enhanced radiosensitivity, as well as the modulation of multiple signaling pathways, such as the PI3K/AKT and NF-κB signaling pathways. Additionally, paeonol can prevent adverse effects on the heart, liver, and kidneys induced by anticancer therapy. Despite numerous studies exploring paeonol’s therapeutic potential in cancer, no specific reviews have been conducted. Therefore, this review provides a systematic summary and analysis of paeonol’s anticancer effects, prevention of side effects, and the underlying mechanisms involved. This review aims to establish a theoretical basis for the adjunctive strategy of paeonol in cancer treatment, ultimately improving the survival rate and enhancing the quality of life for cancer patients.

show abstract

Comparison of short‐term outcomes following minimally invasive versus open Sweet esophagectomy for Siewert type II adenocarcinoma of the esophagogastric junction

Cited by 3 publications

References 22 publications

Application of computed tomography-based radiomics in differential diagnosis of adenocarcinoma and squamous cell carcinoma at the esophagogastric junction

Application of computed tomography-based radiomics in differential diagnosis of adenocarcinoma and squamous cell carcinoma at the esophagogastric junction

Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Pharmacological effects and mechanisms of paeonol on antitumor and prevention of side effects of cancer therapy

Contact Info

Product

Resources

About